Abstract
Chronic liver disease results from a variety of causes such as hepatitis virus infections, autoimmune processes and alcohol consumption. Its complications include fat deposition, hemodynamic changes and fibrosis. Clinically there may be progression to portal-hypertension and porto-systemic encephalopathy. Pioneering research from the laboratory of Kunos at NIH has stressed the importance of endocannabinoids (ECs) as mediators of some of the pathological processes in chronic liver disease. The present review summarizes the literature on the association between ECs and liver disease, as well as the therapeutic potential of ECs and exogenous cannabinoids in liver disease with emphasis on hepatic encephalopathy.
Keywords: Endocannabinoids, Liver Disease, Hepatic Encephalopathy, Chronic liver, autoimmune processes, hemodynamic, fibrosis, portal-hypertension, pathological processes
Current Pharmaceutical Design
Title: Endocannabinoids in Liver Disease and Hepatic Encephalopathy
Volume: 14 Issue: 23
Author(s): Iddo Magen, Yosefa Avraham, Elliot Berry and Raphael Mechoulam
Affiliation:
Keywords: Endocannabinoids, Liver Disease, Hepatic Encephalopathy, Chronic liver, autoimmune processes, hemodynamic, fibrosis, portal-hypertension, pathological processes
Abstract: Chronic liver disease results from a variety of causes such as hepatitis virus infections, autoimmune processes and alcohol consumption. Its complications include fat deposition, hemodynamic changes and fibrosis. Clinically there may be progression to portal-hypertension and porto-systemic encephalopathy. Pioneering research from the laboratory of Kunos at NIH has stressed the importance of endocannabinoids (ECs) as mediators of some of the pathological processes in chronic liver disease. The present review summarizes the literature on the association between ECs and liver disease, as well as the therapeutic potential of ECs and exogenous cannabinoids in liver disease with emphasis on hepatic encephalopathy.
Export Options
About this article
Cite this article as:
Magen Iddo, Avraham Yosefa, Berry Elliot and Mechoulam Raphael, Endocannabinoids in Liver Disease and Hepatic Encephalopathy, Current Pharmaceutical Design 2008; 14 (23) . https://dx.doi.org/10.2174/138161208785740063
DOI https://dx.doi.org/10.2174/138161208785740063 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Treatment of Obesity, Food Intake, and Reversal of Metabolic Disorders
Current Nutrition & Food Science Epidemiology, Prognosis and Prevention of Non-Traumatic Intracerebral Hemorrhage
Current Pharmaceutical Design Editorial
Recent Patents on CNS Drug Discovery (Discontinued) Acute and Sub-acute Oral Toxicity Assessment of a Standardized Polyherbal Preparation POL-6 in Rats
The Natural Products Journal Dyslipidaemia Related to Insulin Resistance and Cardiovascular Disease in South Asian and West African Populations
Current Pharmaceutical Design Synthesis of Novel Spirooxindole Derivatives Using N-Phenylpiperazine as an Organocatalyst
Letters in Organic Chemistry Self-care improvement after a pharmaceutical intervention in elderly type 2 diabetic patients
Current Diabetes Reviews Patient Attitudes Toward Western Medicine and the Future of Chinese Medicine for Spondyloarthritis
Current Rheumatology Reviews Recurrent Left Atrial Low-grade Malignant Inflammatory Myofibroblastic Tumor Characterized by Cardiovascular Magnetic Resonance
Current Medical Imaging Static Cerebral Blood Flow Autoregulation in Humans
Current Hypertension Reviews Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Antihypertensive Drugs Metabolism: An Update to Pharmacokinetic Profiles and Computational Approaches
Current Pharmaceutical Design Cardiovascular Risk in Perimenopausal Women
Current Vascular Pharmacology Correlation of Urine Biomarkers: Microalbuminuria and Spot Urine Protein among Diabetic Patients. Application of Spot Urine Protein in Diabetic Kidney Disease, Nephropathy, Proteinuria Estimation, Diagnosing and Monitoring
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Endothelial Dysfunction and Angiogenesis in Autosomal Dominant Polycystic Kidney Disease
Current Hypertension Reviews Primary Management of Metastatic Colorectal Cancer with Bevacizumab. Review Article Focusing on Efficacy
Current Cancer Therapy Reviews Co-ultraPEALut: Role in Preclinical and Clinical Delirium Manifestations
CNS & Neurological Disorders - Drug Targets Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Cerebral White Matter Lesions, Risk of Stroke and Cerebrovascular Protection with Angiotensin Receptor Blockers
Current Drug Therapy Subject Index To Volume 1
Recent Patents on Cardiovascular Drug Discovery